Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

U Blank

Showing results (91-100 of 317) with videos related to

Pageof 32
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2011
Ipilimumab-induced sarcoidosis in a patient with metastatic melanoma undergoing complete remissionWouter V Vogel, Aurelie Guislain, Pia Kvistborg, et al.
European Journal of Cancer (Oxford, England : 1990)|February 19, 2015
Vemurafenib for BRAF V600 mutated advanced melanoma: results of treatment beyond progressionA Scholtens, M H Geukes Foppen, C U Blank, et al.
European Urology|October 3, 2018
The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial CancerNick van Dijk, Samuel A Funt, Christian U Blank, et al.
Molecular Immunology|November 1, 1986
Molecular heterogeneity of murine IgG-BFC Neauport-Sautes, U Blank, M Daëron, et al.
Applied Clinical Informatics|October 30, 2025
Development and Evaluation of a Web-Based Outcome Database for Advanced Melanoma with Rare BRAF MutationsSusanne Dugas-Breit, Christian Menzer, Christian U Blank, et al.
The Journal of Experimental Medicine|January 6, 2000
The Src homology 2 domain of Vav is required for its compartmentation to the plasma membrane and activation of c-Jun NH(2)-terminal kinase 1R Arudchandran, M J Brown, M J Peirce, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 4, 2017
Short-term CTLA-4 blockade directly followed by PD-1 blockade in advanced melanoma patients: a single-center experienceA Meerveld-Eggink, E A Rozeman, F Lalezari, et al.
JCO Precision Oncology|February 17, 2022
Profound Immunotherapy Response in Mismatch Repair-Deficient Breast CancerMarleen Kok, Hugo M Horlings, Petur Snaebjornsson, et al.
Journal of Cancer Survivorship : Research and Practice|May 5, 2026
Long-term cognitive function after treatment with immune checkpoint inhibition for melanomaMaryse J Luijendijk, Elaine A C Albers, Mees Egeler, et al.
Pigment Cell & Melanoma Research|October 25, 2019
Switch to checkpoint inhibition after targeted therapy at time of progression or during ongoing response: A retrospective single-centre experience in patients with BRAF-mutated melanomaIrene L M Reijers, Elisa A Rozeman, Sofie Wilgenhof, et al.
Pageof 32

Showing results (91-100 of 317) with videos related to

Sort By:
Pageof 32
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2011
Ipilimumab-induced sarcoidosis in a patient with metastatic melanoma undergoing complete remissionWouter V Vogel, Aurelie Guislain, Pia Kvistborg, et al.
European Journal of Cancer (Oxford, England : 1990)|February 19, 2015
Vemurafenib for BRAF V600 mutated advanced melanoma: results of treatment beyond progressionA Scholtens, M H Geukes Foppen, C U Blank, et al.
European Urology|October 3, 2018
The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial CancerNick van Dijk, Samuel A Funt, Christian U Blank, et al.
Molecular Immunology|November 1, 1986
Molecular heterogeneity of murine IgG-BFC Neauport-Sautes, U Blank, M Daëron, et al.
Applied Clinical Informatics|October 30, 2025
Development and Evaluation of a Web-Based Outcome Database for Advanced Melanoma with Rare BRAF MutationsSusanne Dugas-Breit, Christian Menzer, Christian U Blank, et al.
The Journal of Experimental Medicine|January 6, 2000
The Src homology 2 domain of Vav is required for its compartmentation to the plasma membrane and activation of c-Jun NH(2)-terminal kinase 1R Arudchandran, M J Brown, M J Peirce, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 4, 2017
Short-term CTLA-4 blockade directly followed by PD-1 blockade in advanced melanoma patients: a single-center experienceA Meerveld-Eggink, E A Rozeman, F Lalezari, et al.
JCO Precision Oncology|February 17, 2022
Profound Immunotherapy Response in Mismatch Repair-Deficient Breast CancerMarleen Kok, Hugo M Horlings, Petur Snaebjornsson, et al.
Journal of Cancer Survivorship : Research and Practice|May 5, 2026
Long-term cognitive function after treatment with immune checkpoint inhibition for melanomaMaryse J Luijendijk, Elaine A C Albers, Mees Egeler, et al.
Pigment Cell & Melanoma Research|October 25, 2019
Switch to checkpoint inhibition after targeted therapy at time of progression or during ongoing response: A retrospective single-centre experience in patients with BRAF-mutated melanomaIrene L M Reijers, Elisa A Rozeman, Sofie Wilgenhof, et al.
Pageof 32